Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2009-04-21 | Paul Goddard, Ph.D. has served as Chairman of our board of directors since November 2000. Dr. Goddard has served as Chief Executive Officer for ARYx Therapeutics, Inc., a public biopharmaceutical company, since 2005 and Chairman of its board of directors since 2003. He has also been a director of Adolor Corporation Inc, since 2000 and of Onyx Pharmaceuticals, Inc. since 1997. From 1998 to 2000, Dr. Goddard was President and Chief Executive Officer of Elan Corporation, plc's pharmaceutical division. From 1991 to 1998, Dr. Goddard served as Chairman and Chief Executive Officer of Neurex Corporation. In 1998, Neurex was acquired by Elan. Prior to Neurex, Dr. Goddard held various senior management positions at SmithKline Beecham. The following table shows for 2008 certain information with respect to the compensation of all of our non-employee directors and our chairman. Paul Goddard received $100,701 in total compensation. |
| 2010-04-23 | Paul Goddard, Ph.D. has served as Chairman of our Board since November 2000. Dr. Goddard’s annual cash retainer for his services as chairman of our Board is $30,000, plus participation in the same equity compensation structure as the other non-employee directors. Dr. Goddard received a restricted stock award in 2009 of 70,000 shares of our common stock, which vested 35,000 shares on May 27, 2009 and 35,000 shares on January 2, 2010. |
| 2011-06-03 | Paul Goddard, Ph.D. has served as Chairman of our Board since November 2000. Dr. Goddard's annual cash retainer for his services as Chairman of our Board is $30,000, plus participation in the same equity compensation structure and in the prospective cash compensation as the other non-employee Directors. Dr. Goddard received restricted stock awards in 2010 of 109,933 shares of our common stock. The restricted stock awards vested 14,042 shares on May 20, 2010 and 47,946 shares on November 20, 2010, and 47,945 shares are scheduled to vest on the day prior to the next annual meeting. The following table shows 2010 compensation for all of our non-employee Directors and our Chairman. Paul Goddard, Ph.D. Fees Earned or Paid in Cash: $30,000, Stock Awards: $97,101, Total: $127,101. |
| 2012-04-24 | Paul Goddard, Ph.D. has served as Chairman of our Board since November 2000. Dr. Goddard's annual cash retainer for his services as Chairman of our Board is $30,000, plus participation in the same equity compensation structure and in the prospective cash compensation as the other non-employee directors. Dr. Goddard received a stock option grant in 2011 to purchase up to 400,000 shares of our common stock. The options vest: (i) in equal monthly installments over a twelve-month period from the date of grant; and (ii) if such options are not 100% vested on the day before our next annual meeting of stockholders, the remaining unvested options shall vest, such that the grant is 100% vested. The following table shows 2011 compensation for all of our non-employee directors and our Chairman. Paul Goddard, Ph.D. $37,500 Fees Earned or Paid in Cash, $83,880 Option Awards, $0 Stock Awards, $0 All Other Compensation, $121,380 Total. |
Data sourced from SEC filings. Last updated: 2026-02-03